We also used claims to exclude 12 820 men (1%) who had symptoms (eg, hematuria, back pain, weight loss, urinary obstruction) during the 3 months before their index PSA was performed, because this PSA was considered a diagnostic test rather than a screening test. This analysis is based on...
Aizer and D'Amico provide an excellent overview of current prostate-specific antigen (PSA) screening controversies, highlighting the strengths and weaknesses of recent prospective randomized trials of population-based screening. They emphasize that two of the trials have shown an improvement in prostate...